Physician profile
Michael A Puente
NPI 1982640074
$7,602.26
in general payments reported to CMS, 2019-2025
49 companies · $1,327 in 2025
The $1,327 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $881 · 2020: $588 · 2021: $1,065 · 2022: $1,127 · 2023: $1,163 · 2024: $1,451 · 2025: $1,327.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,932 · Education: $8.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,932.28 |
| Education | $8.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,531.36 | 2021-2025 | |
| Ucb, INC. | $622.16 | 2019-2025 | Briviact, Fintepla, Rystiggo |
| Amgen INC. | $390.20 | 2019-2025 | Uplizna |
| Acadia Pharmaceuticals INC | $381.56 | 2019-2025 | Nuplazid |
| Eisai INC. | $340.41 | 2021-2025 | |
| Biogen, INC. | $265.88 | 2019-2025 | Vumerity, Tysabri, Skyclarys |
| Allergan, INC. | $221.15 | 2020 | |
| Pfizer INC. | $210.61 | 2023-2024 | |
| Alexion Pharmaceuticals, INC. | $200.51 | 2021-2025 | Ultomiris |
| Mdd US Operations, LLC | $200.48 | 2019-2025 | Apokyn, Xadago, Gocovri |
| Argenx US, INC. | $187.98 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Biohaven Pharmaceuticals, INC. | $160.34 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $155.37 | 2022 | |
| Novartis Pharmaceuticals Corporation | $153.64 | 2019-2025 | |
| Neurelis, INC. | $148.15 | 2024-2025 | Valtoco |
Show all 48 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Puente listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.